Leukaemia Trial, Recruiting (NCT00662090)

Leukaemia Trial, Recruiting NCT00662090 Sponsor: University Hospital Freiburg Condition: Leukaemia

Printed from Voxsanity (voxsanity.com.au) — NCT00662090 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Leukaemia

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

The patient's caregivers (and the patient themselves, where possible) have agreed in writing to take part in the trial.
The patient has a confirmed diagnosis of MDS (myelodysplastic syndrome) or JMML (juvenile myelomonocytic leukemia), confirmed through cell appearance and genetic testing.
Patients with myeloid leukemia related to Down syndrome who are older than 6 years of age may be eligible.
The patient is under 18 years of age.

Who may not be able to join:

The patient's caregivers or the patient themselves have not agreed to take part in the trial.
Patients with myeloid leukemia related to Down syndrome who are younger than 6 years of age are not eligible.
Patients who have taken part in another clinical study within the last 4 weeks may not be eligible — though exceptions may apply for studies focused on optimising cancer treatment, bone marrow failure disorders, or diagnostic studies (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 14 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Charlotte M. Niemeyer, M.D., University of Freiburg

Phone: 49-761-270

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT00662090

Sponsor: University Hospital Freiburg

Phase: Not Applicable

Status: Recruiting

Condition: Leukaemia

Trial contact: 49-761-270

More information: https://clinicaltrials.gov/study/NCT00662090

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

The patient's caregivers (and the patient themselves, where possible) have agreed in writing to take part in the trial.
The patient has a confirmed diagnosis of MDS (myelodysplastic syndrome) or JMML (juvenile myelomonocytic leukemia), confirmed through cell appearance and genetic testing.
Patients with myeloid leukemia related to Down syndrome who are older than 6 years of age may be eligible.
The patient is under 18 years of age.

Who may not be able to join:

The patient's caregivers or the patient themselves have not agreed to take part in the trial.
Patients with myeloid leukemia related to Down syndrome who are younger than 6 years of age are not eligible.
Patients who have taken part in another clinical study within the last 4 weeks may not be eligible — though exceptions may apply for studies focused on optimising cancer treatment, bone marrow failure disorders, or diagnostic studies (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 14 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University Hospital Freiburg

Registry

ClinicalTrials.gov

Start date

1 April 2010

Est. completion

1 December 2027

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

To evaluate the frequency of the different subtypes of MDS in childhood and adolescence by a standardized diagnostic approach; To evaluate the frequency of cytogenetic and molecular abnormalities

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov